Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Pharmacol Exp Ther ; 368(3): 514-523, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30606762

RESUMEN

Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor γ (PPARγ) agonists that represent an effective class of insulin-sensitizing agents; however, clinical use is associated with weight gain and peripheral edema. To elucidate the role of PPARγ expression in endothelial cells (ECs) in these side effects, EC-targeted PPARγ knockout (Pparg ΔEC) mice were placed on a high-fat diet to promote PPARγ agonist-induced plasma volume expansion, and then treated with the TZD rosiglitazone. Compared with Pparg-floxed wild-type control (Pparg f/f) mice, Pparg ΔEC treated with rosiglitazone are resistant to an increase in extracellular fluid, water content in epididymal and inguinal white adipose tissue, and plasma volume expansion. Interestingly, histologic assessment confirmed significant rosiglitazone-mediated capillary dilation within white adipose tissue of Pparg f/f mice, but not Pparg ΔEC mice. Analysis of ECs isolated from untreated mice in both strains suggested the involvement of changes in endothelial junction formation. Specifically, compared with cells from Pparg f/f mice, Pparg ΔEC cells had a 15-fold increase in focal adhesion kinase, critically important in EC focal adhesions, and >3-fold significant increase in vascular endothelial cadherin, the main component of focal adhesions. Together, these results indicate that rosiglitazone has direct effects on the endothelium via PPARγ activation and point toward a critical role for PPARγ in ECs during rosiglitazone-mediated plasma volume expansion.


Asunto(s)
Tejido Adiposo/metabolismo , Células Endoteliales/metabolismo , Hipoglucemiantes/farmacología , PPAR gamma/deficiencia , Rosiglitazona/farmacología , Remodelación Vascular/fisiología , Tejido Adiposo/irrigación sanguínea , Tejido Adiposo/efectos de los fármacos , Animales , Células Endoteliales/efectos de los fármacos , Eliminación de Gen , Masculino , Ratones , Ratones Transgénicos , PPAR gamma/genética , Volumen Plasmático/efectos de los fármacos , Volumen Plasmático/fisiología , Remodelación Vascular/efectos de los fármacos
2.
Methods Mol Biol ; 1966: 203-210, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31041749

RESUMEN

The chemical carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) has been used for many decades to induce skin, mammary, and ovarian tumors in mice. There are however a wide range of doses and treatment regimens in the literature that sometimes confound comparative interpretations of different studies. Here we describe a proven method to generate in vivo DMBA-mediated murine mammary tumors to enable consistent studies of the cell targeted role of genes of interest during this process.


Asunto(s)
9,10-Dimetil-1,2-benzantraceno/toxicidad , Neoplasias de la Mama/metabolismo , Pruebas de Carcinogenicidad/métodos , Neoplasias Mamarias Experimentales/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Animales , Neoplasias de la Mama/inducido químicamente , Carcinógenos/toxicidad , Femenino , Neoplasias Mamarias Experimentales/inducido químicamente , Ratones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA